CHECKIT PLC (CKT) — Investment Research Note
Executive summary
Checkit operates a hardware-enabled SaaS platform that combines IoT sensors, digital workflows and analytics for "deskless" frontline operations across healthcare, biopharma, retail and facilities management. Across the five-year period the company has executed a transition from a low-margin, project-based hardware business into a 96%-recurring software model — culminating in a structural cost reset (£4m annualised savings, headcount cut from 165 to 117) that delivered Adjusted EBITDA profitability of £0.3m in FY26 versus a £2.3m loss in FY25 2026-04-21 final results. The single most important point for valuation today is the Formal Sale Process announced on 26 March 2026: the Board commenced it after receiving six unsolicited expressions of interest, framing the current public-market valuation as failing to reflect a now-profitable, debt-free recurring-revenue platform.
Fair value estimate
- Fair value range: 32p – 52p per share (implied market cap £35m – £56m)
- Mid-point: ~42p / £45m
- Methodology: EV/ARR multiple, sense-checked against EV/Revenue and the Formal Sale Process backdrop. With ARR of £14.3m, net cash of £3.0m, no debt, and a freshly-profitable Adjusted EBITDA run-rate (H2 FY26 alone was £0.8m EBITDA, implying ~£1.6m annualised), peer SaaS multiples of 2.0x – 3.5x ARR feel reasonable for a sub-scale but profitable, hardware-moated platform.
- 2.0x ARR + £3m cash = £31.6m mcap = ~29p (downside, no takeover)
- 2.75x ARR + £3m cash = £42.3m mcap = ~39p (central, standalone fair)
- 3.5x ARR + £3m cash = £53.1m mcap = ~49p (upside / takeover case)
- Cross-check (EV/Sales): 2.5x – 3.5x £13.7m revenue ⇒ £37m – £51m EV ⇒ £40m – £54m mcap ⇒ 37p – 50p.
- Cross-check (takeover comps): hardware-enabled SaaS deals in this segment have historically cleared at 3-5x ARR; the Board's commentary that fair value is "well below" current implies they expect bids above the current 24.5p.
- vs. current £26.5m mcap (~24.5p): mid-point upside +63%; range spans +30% to +112%.
Sector context
ICB classification (Technology / Technology) is correct — specifically vertical SaaS + Industrial IoT. Quality is above average on revenue mix (96% recurring, 95% gross retention), in line on growth (underlying ARR +5%), and above average on balance sheet (net cash, no debt). Margins are still sub-scale (Adjusted EBITDA ~2%) but the fixed-cost base post-restructuring sets up strong incremental drop-through. Closest UK-listed comparables: Crimson Tide (now-aborted merger target, similar size/profile), Eagle Eye Solutions and Cerillion for the SaaS framing; IQGeo for the vertical-IoT-software framing.
Investment thesis
- Cheap recurring-revenue platform with realistic takeover optionality. The Formal Sale Process commenced 26 March 2026 followed six unsolicited inbounds; the Board explicitly states the public valuation does not reflect the asset 2026-04-21 final results. Even absent a deal, ~1.6x EV/ARR is well below SaaS norms.
- Cost reset has visibly created operating leverage. Annualised cost base cut by £4m, headcount from 165 → 117, EBITDA breakeven ARR threshold materially lower. H2 FY26 delivered £0.8m EBITDA and was cash-generative on broadly flat ARR — incremental ARR should now drop disproportionately to profit 2026-04-21 final results.
- Hardware-enabled moat protects against AI commoditisation. Unlike pure application-layer SaaS, Checkit integrates physical sensors, embedded workflows and Asset Intelligence (AI/ML) into customer operations — high switching costs (95% GRR, 104% NRR ex-one customer) and a defensible data flywheel as Asset Intelligence accumulates structured operational data 2026-04-21 final results.
Key risks
- Formal Sale Process may not deliver. "There can be no certainty that any offers will be made… that any sale will be concluded" 2026-04-21 final results. If the process ends without a bid, the share price would likely give back the recent takeover premium.
- Customer concentration and recent US churn. One customer represents 13% of revenue; FY26 ARR was held back by a £0.4m contraction from a single US customer 2026-04-21 final results, 2025-08-26 interims. A repeat would erase underlying ARR growth.
- Sub-scale balance sheet for a small-cap. Net cash of only £3.0m and an FY26 cash outflow of £2.1m provides limited buffer if profitability slips before the H2 trajectory annualises (not disclosed but inferred from balance sheet).
Operating leverage
This is a classic operating-leverage story now in inflection. The visible mechanics: revenue was essentially flat year-on-year (£14.1m → £13.7m), yet Adjusted EBITDA swung +£2.6m (loss £2.3m → profit £0.3m). The H1→H2 FY26 EBITDA progression (–£0.5m to +£0.8m) on broadly similar revenue is even more striking. Gross margin is structurally high at 72% (FY26: £9.9m gross profit / £13.7m revenue). Operating costs charged to the income statement fell 18% to £9.8m, and 96% of revenue is now recurring — meaning each incremental £1m of ARR carries near-gross-margin contribution (~70p) against an essentially fixed cost base 2026-04-21 final results. A 10-20% revenue beat would plausibly more than double operating profit at this scale: 15% on £13.7m = £2m extra revenue × 70% GM = ~£1.4m incremental EBITDA, on a base of £0.3m. Management's own framing explicitly leans on "inherent operating leverage" and a "materially lower EBITDA breakeven point." Caveat: ~£1.8m of development costs are still being capitalised, so reported EBITDA flatters true cash margins.
Value-trap signals
- Revenue stagnation (–2% reported, +2% constant-currency ARR) rather than the double-digit SaaS growth the multiple framework assumes.
- Repeated guidance reset in FY25 (April 2025 strategic update cut prior FY25 LBITDA guidance further; growth guidance reduced to 2-5%) followed two prior years of in-line/beat results.
- Aborted Crimson Tide merger consumed £0.3m of professional fees and management attention through 2024-25 2025-08-26 interims.
- Repeated chairman commentary on the "disparity" between performance and share price across three consecutive annual reports suggests structural investor scepticism, not just market mispricing.
Earnings vs. expectations
- FY23 trading update (Feb 2023): ARR £11.5m vs consensus £10.8m — BEAT.
- FY24 (Apr 2024): in line with Board/market expectations; LBITDA £3.4m, a 46% improvement — MET/BEAT.
- H1 FY25 (Sep 2024): ARR +9%, in line — MET.
- FY25 outlook (Apr 2025 strategic update): management explicitly CUT prior guidance — growth now 2-5% (vs previously higher), LBITDA worse than the £0.7m loss previously guided.
- H1 FY26 (Aug 2025): in line with reset expectations — MET.
- FY26 trading update (Feb 2026): Adjusted EBITDA at break-even ahead of expectations; net cash £3.0m ahead of expectations — BEAT.
- FY26 final results (Apr 2026): EBITDA £0.3m vs break-even indicated — BEAT again.
Pattern: small beats during 2022-24, a notable downgrade in April 2025, then sequential beats on the reset bar through 2025-26. The current trajectory is meet-to-beat, but on a lowered base.
Conviction
3 — moderate. Anchored by: (i) clean, well-disclosed AIM accounts with consistent definitions of ARR/NRR/GRR; (ii) the Formal Sale Process providing a market-tested valuation anchor; (iii) recurring revenue mix and net-cash balance sheet limit downside scenarios. Limited by: (a) wide range between standalone fair value (~30p) and takeover-clearing levels (~50p+) hinges on the sale process outcome — binary in nature; (b) sub-scale absolute profit (£0.3m EBITDA) means the EV/ARR multiple is doing most of the work in the valuation.